SIRIO(SZ:300791)2021-08-25 16:00Financial Performance - The company's operating revenue for the reporting period reached ¥1,165,031,370.37, representing a 27.22% increase compared to ¥915,765,854.71 in the same period last year[38]. - The net profit attributable to shareholders of the listed company was ¥145,779,109.52, up 17.33% from ¥124,249,473.56 in the previous year[38]. - The net profit after deducting non-recurring gains and losses was ¥133,239,353.27, reflecting a 28.84% increase from ¥103,413,829.95 in the same period last year[38]. - The net cash flow from operating activities was ¥158,344,477.38, which is a 43.03% increase compared to ¥110,706,822.08 in the previous year[38]. - The total assets at the end of the reporting period amounted to ¥3,794,113,185.98, a 43.19% increase from ¥2,649,636,693.93 at the end of the previous year[38]. - The net assets attributable to shareholders of the listed company were ¥2,460,739,899.62, up 12.74% from ¥2,182,687,275.64 at the end of the previous year[38]. - The basic earnings per share for the reporting period was ¥0.81, an increase of 17.39% from ¥0.69 in the same period last year[38]. - The diluted earnings per share was ¥0.79, reflecting a 14.49% increase from ¥0.69 in the previous year[38]. - The company received government subsidies amounting to ¥5,700,785.29 during the reporting period[44]. - The total non-recurring gains and losses amounted to ¥12,539,755.86 for the reporting period[44]. Sales and Market Performance - Domestic sales revenue reached 735 million CNY, growing by 41.5%, while overseas sales revenue was 427 million CNY, up by 11.7%[57]. - Revenue from nutritional gummies increased by 113.69% year-on-year to 241,583,231.62, driven by new production lines and increased orders[103]. - Revenue from powder products grew by 42.67% year-on-year to 170,496,696.69, attributed to increased orders[103]. - Revenue from functional beverages rose by 83.35% year-on-year to 122,660,511.14, due to capacity release and increased orders[103]. - Revenue from the China region increased by 41.46% year-on-year to 735,305,440.31, driven by growth in orders for gummies and beverages[103]. Research and Development - R&D investment amounted to 40.39 million CNY, reflecting a year-on-year increase of 28.6%, with 15 invention patent applications submitted during the period[58]. - The company invested CNY 40.39 million in R&D in the first half of 2021, representing a year-on-year increase of 28.6%[80]. - The company submitted 15 invention patent applications in the first half of 2021, completing multiple new product research and development projects[80]. - The company has a research team of 338 members, including 13 PhDs, enhancing its product development capabilities[77]. Production and Operations - The second production line for nutritional gummies at the Ma'anshan facility was launched in January 2021, with an annual capacity of 800 million pieces[60]. - A new beverage workshop was put into operation, consolidating existing production lines for improved management and efficiency[60]. - The company plans to add two new beverage production lines in the third quarter, with an annual capacity of 10 million bags[60]. - The company is enhancing operational efficiency through the establishment of a digital factory project focused on lean, intelligent, and automated manufacturing[62]. - The company has established production bases in Shantou, Ma'anshan, and Falkenhagen, Germany, with capabilities for various dosage forms including soft capsules and gummies[73]. Compliance and Governance - The company emphasizes compliance with environmental laws and has not faced any penalties for violations during the reporting period[156]. - The company is committed to improving corporate governance and ensuring transparent information disclosure to protect shareholder rights[157]. - The company has adhered to all commitments regarding share transfers and lock-up periods as of the announcement date[168]. - The company’s board and executives are responsible for ensuring the accuracy and timeliness of disclosures related to the prospectus[174]. Shareholder and Financial Commitments - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[17]. - The company has committed to a cash dividend policy, distributing at least 30% of net profits to shareholders annually[180]. - The company plans to distribute at least 45% of the average distributable profit over the last three years in cash dividends[183]. - The company will prioritize cash dividends when conditions for cash distribution are met, with a minimum cash dividend ratio of 80% during mature stages without significant capital expenditures[183]. - The controlling shareholder and actual controllers pledged to increase their stock holdings by at least 30% of the cash dividends received in the previous year[171]. Strategic Initiatives - The company is exploring potential acquisitions to enhance its product portfolio and market reach[182]. - The company expects revenue growth of 20% for the full year 2021, driven by new product launches and market expansion strategies[182]. - A new product line is set to launch in Q3 2021, projected to contribute an additional RMB 20 million in revenue[182]. - The company has established a long-term incentive plan for key employees, effective until September 2024[180]. Risk Management - The company has established an emergency response team to monitor and assess the impact of the ongoing COVID-19 pandemic on overseas production and export logistics[8]. - The company emphasizes product quality management, leveraging 20 years of experience in the nutrition and health food sector to mitigate quality risks[9]. - The company has a professional regulatory department to track and interpret industry regulations, ensuring compliance and adaptability to policy changes[13]. - The company exports primarily to North America and Europe, making it susceptible to significant exchange rate fluctuations that could impact its operating performance[15].